Five veteran pitchers. Five different stories. And yet, the same underlying question hangs over all of them as camps break and the 2026 season comes into focus: how much is left?

The answer, based on what we've seen this spring, is more than most anticipated.

Let's start with Justin Verlander, because the numbers demand it: Fifteen strikeouts in 10 innings, a fastball touching 96, and a strikeout percentage sitting in the 99th percentile of the sport. He's 43 years old, back in Detroit where his career began, and he does not look like a pitcher in decline. He looks like a pitcher who has figured something out.

The skepticism is warranted, as it always is with pitchers his age. History has its cautionary tales. But Verlander already silenced similar doubts last season with San Francisco, making 29 starts and posting a 3.85 ERA at 42. The Tigers didn't sign him to anchor a rotation; they signed him to complement one. With Tarik Skubal and Framber Valdez around him, Verlander doesn't need to be the best pitcher on the staff, he just needs to be reliable. If he approaches 27 starts and holds an ERA in the mid-3.00 range, Detroit's rotation becomes genuinely difficult to navigate. That's a real outcome. Not a guarantee, but a real one.

Chris Sale, meanwhile, is operating at a different level entirely. Six innings. One run. Two hits. A spring ERA of 2.75. Atlanta named him its Opening Day starter and then signed him through 2027, which tells you everything about how the organization views and values him. This isn't a team hedging on a veteran, but a team that believes.

And honestly, the belief is earned. Sale's 2025 was as good as it gets: a 2.58 ERA, 165 strikeouts, a 1.07 WHIP. He was the best pitcher on one of the best teams in baseball. If this spring is any indication, 2026 follows the same trajectory. The Braves give him run support and a bullpen capable of protecting leads. The rotation around him is capable. There's no reason to think the production changes unless Sale's body does. That, unfortunately, has always been the caveat with him. The injury history is real and it's long. But right now, in the spring of 2026, he looks as sharp as he has at any point in the last five years.

The Toronto situation is more complicated and more urgent. Multiple sources have confirmed that the Blue Jays are heading into the season without José Berríos, Shane Bieber, and Trey Yesavage, all of whom are dealing with arm injuries of varying severity. That leaves Max Scherzer as the most dependable arm in the rotation. He's 41. And he has a 0.00 ERA in 13.2 spring innings.

Scherzer's fastball is back up to 95.8 mph, ahead of where he was in live BP sessions, and Toronto's pitching staff has noted that he looks ahead of where he was at this point last season. The Blue Jays were already planning for him to open the year as a starter, and now he's their most important one. If the arm holds – and it held through most of 2025, including a World Series appearance – Toronto has a legitimate front-of-rotation presence. If it doesn't, the organizational depth becomes a serious problem in a hurry for a team with real playoff aspirations. How Scherzer performs in April and May will go a long way toward determining whether those aspirations survive the summer.

Gerrit Cole is a different conversation entirely. He's not part of the 2026 season yet, but he's working toward it.

Cole's Tommy John surgery was March 11, 2025. His first spring appearance (one inning, 10 pitches, two fastballs at 98) came March 19, 2026. Those numbers inspire optimism. But the Yankees are not rushing this. A late May or early June return is the current framework, and even that depends on how his body responds over the coming weeks. Multiple simulated games, two-to-three inning outings, and a minor league rehab stint all sit between where he is now and where he needs to be.

The velocity is encouraging, and it always returns before the command does. Cole will need regular-season action before we know whether he's truly himself again. What's realistic? A second-half contributor who helps stabilize a Yankees rotation leaning heavily on Max Fried and Carlos Rodón. What's possible, if everything goes right? One of the best pitchers in the American League making a legitimate Cy Young push from August onward. New York won't count on the possible. But they won't dismiss it either.

Then there's Jacob DeGrom, who remains the most delicate and most tantalizing arm in the sport.

His spring debut with a  97.6 mph average fastball velocity, a 71 percent strike rate, no injury aftermath, generated the kind of exhale that only comes from covering a pitcher who has given his fanbase and his organization years of heartbreak between brilliance. In 2025, DeGrom made 172.2 innings of work look almost routine. For him, it was anything but. The Rangers managed him carefully early in the year and watched him develop into one of the better pitchers in the American League. Now he's targeting 200 innings in 2026. He said after the season that he felt he could've kept going, and that's not a small thing.

Texas surrounded him this winter: MacKenzie Gore is in the rotation, Nathan Eovaldi is still there, and the lineup provides legitimate run support. If DeGrom reaches 200 innings in a healthy, sharp, consistent way, we're talking about a Cy Young campaign in a very real sense. The AL West becomes a different kind of race. The question, as it always is with DeGrom, is simply whether the body cooperates. If it does, there's no ceiling worth naming.

So where does this leave us as the season begins?

Sale is the safest projection and the most likely to finish the year as a top-five pitcher in his league, provided his health holds. Verlander is the most pleasant surprise in waiting, a 43-year-old who might just manufacture 26 quality starts for a Tigers team with genuine postseason ambitions. Scherzer is the most important variable on a team with real stakes and a paper-thin safety net behind him. Cole is a second-half story for a Yankees team that won't panic during his absence but will certainly be better for his return. And DeGrom is baseball's permanent what-if, the pitcher every team in the sport would build around if the body came with a warranty.

None of these stories end neatly; they rarely do. But the spring has offered something worth holding onto: all five pitchers are still relevant, still competitive, and still throwing hard. In a sport where careers end quietly and often without warning, that's not a small thing to say.